skip to Main Content

Novel Combination Shows Promising Responses in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The combination of the novel tumor-associated macrophage (TAM)-targeting agent cabiralizumab and the PD-1 inhibitor nivolumab (Opdivo) resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer, according to findings from a phase I study presented at the 2017 SITC Annual Meeting.

At the time of the presentation, cabiralizumab plus nivolumab elicited a confirmed objective response in 4 of 31 (13%) efficacy-evaluable heavily pretreated patients with pancreatic cancer. Read more . . .

Back To Top